VTRS:NSD-Viatris Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 13

Change

+0.07 (+0.54)%

Market Cap

USD 13.87B

Volume

8.25M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

-1.50 (-1.18%)

USD 12.37B
ITCI Intracellular Th

-0.27 (-0.31%)

USD 9.17B
LNTH Lantheus Holdings Inc

-5.39 (-6.33%)

USD 7.63B
ALKS Alkermes Plc

+0.01 (+0.03%)

USD 4.73B
ALVO Alvotech

-0.23 (-1.89%)

USD 3.67B
HCM HUTCHMED DRC

-0.44 (-2.52%)

USD 3.18B
AMPH Amphastar P

-2.23 (-4.67%)

USD 2.29B
SUPN Supernus Pharmaceuticals Inc

-0.06 (-0.16%)

USD 1.93B
HROW Harrow Health Inc

+1.89 (+3.79%)

USD 1.86B
KNSA Kiniksa Pharmaceuticals Ltd

-0.37 (-1.61%)

USD 1.59B

ETFs Containing VTRS

FHH:CA First Trust AlphaDEX US H.. 2.26 % 0.77 %

-0.36 (0.00%)

CAD 0.01B
DON WisdomTree U.S. MidCap Di.. 0.00 % 0.38 %

-0.17 (0.00%)

N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

-0.11 (0.00%)

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

-0.27 (0.00%)

N/A
DUSA 0.00 % 0.63 %

N/A

N/A
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

-0.07 (0.00%)

USD 0.02B
RPV Invesco S&P 500® Pure Va.. 0.00 % 0.35 %

+0.25 (+0.00%)

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

-0.32 (0.00%)

N/A
XXM:CA 0.00 % 0.68 %

N/A

N/A
UMI:CA CI U.S. MidCap Dividend I.. 0.00 % 0.41 %

-0.34 (0.00%)

CAD 0.02B
XMMD:LSE Xtrackers - MSCI Emerging.. 0.00 % 0.00 %

-0.26 (0.00%)

N/A
UMI-B:CA CI WisdomTree U.S. MidCap.. 0.00 % 0.00 %

N/A

N/A
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.04% 76% C+ 74% C
Dividend Return 3.32% 67% D+ 61% D-
Total Return 23.36% 77% C+ 75% C
Trailing 12 Months  
Capital Gain 38.89% 79% B- 77% C+
Dividend Return 5.13% 67% D+ 69% C-
Total Return 44.02% 80% B- 79% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.68% 39% F 26% F
Dividend Return -3.22% 42% F 28% F
Total Return 2.45% 67% D+ 57% F
Risk Return Profile  
Volatility (Standard Deviation) 16.25% 100% F 82% B
Risk Adjusted Return -19.84% 33% F 24% F
Market Capitalization 13.87B 100% F 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector